| Name | Title | Contact Details |
|---|
Ossium is building the world`s first bone marrow bank to treat blood cancers, improve organ transplantation, and repair damage from radiation.
TAO Life Sciences invests in and develops early stage medical innovations. Working closely with physicians and researchers from universities and companies, TAO Life Sciences takes new concepts and turns them into reality. TAO Life Sciences is building a pipeline of promising medical device and life science innovations that will impact global healthcare markets and make a significant difference in people's lives. TAO Life Sciences applies its expertise to develop prototypes, demonstrate clinical proof of concept, and secure financial exits for our innovations. We bring design engineering, scientific direction, and business and legal strategy to clinicians' and researchers' new design concepts. In doing so, we have built a diversified pipeline of medical device technologies with significant commercial potential. The Company's principals have successfully brought medical device, diagnostic, therapeutic and other products to market over the past twenty years.
At MicroGEM, we are transforming the landscape of DNA and RNA extraction. Come see how our single-tube extraction workflows can work for you!
At Lexington Regional Health Center, we are redefining health care. By embracing a truly patient-centered care model, we focus on you and your family`s needs. From urgent care and 24-hour emergency services, to radiology and physical therapy, we are here for you. Walking through our doors, you`ll feel right at home, because you are. Between detection and prevention, therapy and recovery, diagnosis and treatment; in the middle of it all, Lexington Regional is your health center.
Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.